Journal Reviews

Orbit journal cover

Teprotumumab for chronic TED

3 February 2023 | | Oculoplastics, Orbit | Chronic, proptosis, teprotumumab, thyroid eye disease

This retrospective case series looks at the use of teprotumumab in nine patients with thyroid eye disease (TED) of clinical activity score ≤one and >nine months duration, in an American cohort. Current European guidelines have suggested the use of teprotumumab...